Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy & Autoimmune Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FCRL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCRL2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin Controlled (<1EU/ug). Sequence Verified. HEK293 Expressed for native glycosylation. |
View FCRL2 Products |
| Gene Delivery | FCRL2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in internalization and binding assays. |
View FCRL2 Products |
| Benchmark Ab | Anti-FCRL2 Benchmark Antibody Recombinant positive control derived from clinical/literature sequences. |
View FCRL2 Products |
| Validator | FCRL2 siRNA Set Target-specific knockdown pool for functional assay validation. |
View FCRL2 Products |
| Related Target A | FCRL5 High-homology subfamily member; essential for cross-reactivity and off-target safety screening. |
View FCRL5 Products |
| Related Target B | FCRL1 B-cell lineage marker sharing structural domains; required for selectivity profiling. |
View FCRL1 Products |
| Related Target C | FCRL3 Subfamily control to ensure therapeutic specificity in autoimmune and oncology pipelines. |
View FCRL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | FCRL1-5 recombinant proteins strictly verified by Mass Spectrometry to guarantee correct domain sequence separation. |
| Internalization Assay Optimization (ADC) | Lentivirus-driven full-length FCRL2 stable cell line construction ensures native membrane conformation and receptor dynamics. |
| Inconsistent Glycosylation in Assays | Exclusively HEK293-expressed ECD proteins preserving authentic human post-translational modifications. |
| Lack of Positive Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
Live FCRL2/CD307b R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Fc Receptor-Like (FCRL) family is gaining significant momentum, driven by the clinical validation of related family members such as FCRL5 (e.g., Cevostamab). As a Type I transmembrane protein selectively expressed on B-cell subsets, FCRL2 (CD307b) represents a highly specific marker for Chronic Lymphocytic Leukemia (CLL) and specific memory B-cell populations. The global pipeline is expanding beyond traditional monoclonal antibodies into next-generation modalities, specifically Antibody-Drug Conjugates (ADCs) and T-cell engaging bispecifics (BiTEs), to exploit FCRL2's restricted expression and rapid internalization kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Oncology Biopharma, Academic Institutes | Chronic Lymphocytic Leukemia (CLL), B-cell Lymphomas | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc fusion proteins) |
| Bispecific Antibodies (CD3 x FCRL2) | Immunotherapy Developers | Refractory B-cell Malignancies | Dual-affinity validation (Requires stable FCRL2-expressing target cells via lentiviral transduction) |
| Monoclonal Antibodies (mAbs) | Autoimmune-focused Biotech | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis | Epitope mapping & subfamily counter-screening (Requires FCRL1/3/5 recombinant panels) |